Anti-inflammatory action:
Particularly noteworthy is the effect ofInhibirelA® on inflammatory bowel diseases such as Crohn's disease (Crohn or ulcerative proctitis - a form of ulcerative colitis affects only the colon)) and ulcerative colitis, significantly reduces the probabilityrecurrence of the disease, relieves symptoms (decreased frequency of stools, normal stool consistency and reduces pain and spasms) and contributes to the normalization of laboratory parameters as velocity of erythrocyte sedimentation rate (ESR) and levels of C-reactive protein (CRP).
Reduces intestinal polyps:
InhibirelA® has a beneficial effect in patients with familial adenomatous polyposis (FAP) - a hereditary disease in which polyps (adenomas) are occurring in the colon, part of which can develop into cancer (colon cancer) - as can greatly reduce the polyps.
Anti-biotic action:
InhibirelA® has also an expressed antibacterial, antimicrobial, antiviral and antifungal activity, which is especially pronounced in infections of the gastrointestinal tract and urinary tract.
Thanks to this effective action InhibirelA®can be successfully countered by infectious agents: H. pillory, Candida, Schistosoma mansoni, Malaria, E. coli, Staphylococcus aureus, Bacillus cereus, Salmonella typhimurium.
In this regard, InhibirelA® may also potentiate and enhance the antibacterial effect of some antibiotics such as: cefixime, cefotaxime, vancomycin and tetracycline.
Ulcers, dyspepsia, gastritis, pancreatitis:
InhibirelA® relieves the symptoms of ulcer, dyspepsia, peptic ulcer and pancreatitis.Protects the gastric mucous layer, reduces the acidity of the stomach contents, regulates the secretion of gastric juices, thereby protecting the gastrointestinal tract from the formation of ulcers. Regulates the function of the pancreas.
Irritable bowel syndrome:
InhibirelA® relieves symptoms in irritable bowel syndrome - representing intestinal motility disorder characterized by chronic recurrent gastrointestinal symptoms (changes in bowel habits, abdominal pain, etc..) In the absence of organic causes.
Biliary insufficiency:
InhibirelA® stimulates bile production and accelerates the emptying of the gallbladder, thereby counteracting the formation of gallstones (cholelithiasis), whose presence is a risk factor for gallbladder cancer.
Hepatoprotective effects:
InhibirelA® has hepatoprotective effects, supporting digestive function of the liver and preventing disability, as a result of excessive alcohol consumption, a diet high in unsaturated fats and other toxic substances, incl. hepatotoxic drugs.